The Readout Loud
412 episodes — Page 9 of 9
Episode 11: Inside the Theranos collapse, Valeant's latest legal lumps, and a few biotech hot takes
What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?
Episode #10: Cohen, Trump, Novartis, oh my; Spark + Amish; Genetic testing at your doc's office?
On today's show, we dig into the no good, very bad day Novartis had when the world got wind of its ties to President Trump's personal attorney, a discussion of how the world's biggest cancer conference used to be the Wild West for investors, and an exploration of one health system's plan to bring genomics to the masses. Also STAT's Eric Boodman joins us to talk about how a pricey new gene therapy has created a fascinating situation in Amish country.
Episode #9 - Bill Gates on deadly flu, Chinese biotech bubbles, Golden State killer genetics
We talk to Bill Gates about the flu that could kill millions. Is China too enamored with biotech startups? And how do you find a cold case killer? Genetics.
Episode #8 - Megamergers, migraines, and biotech's Four Horsemen
What's a good use of $64 billion? Is Big Biotech boring now? And what's the best way to sell hair restoration products to men?
Episode #7 - Coke and Pepsi of lung cancer, a debatable drug price, and a cure for capitalism
Is Bristol-Myers Squibb into self-sabotage? Is Congress coming for Gut Guy? And why does Goldman Sachs love money so much?
Episode #6 - Biotech buyouts, CEO breakups, and The Rock does CRISPR
Why are biotech investors suddenly so exuberant? What does it mean when a CEO scrubs his LinkedIn profile? And can CRISPR turn your dog into a winged hellhound bent on destroying Chicago?
Episode #5 - The FDA's cold shoulder, the latest CAR-T contender, and BuzzFeed's scoop on Grindr
What's it like to be a biotech investor? Do you know where your genetic data are? And what does it mean when the FDA swipes left on your drug?
Episode #4 - Mr. Drug CEO doesn't go to DC, billionaires fighting drug prices, a biotech report card
Why aren't pharma CEOs getting hauled into Congress? Which biotech companies got a failing grade this quarter? And why is there no Kelley Blue Book for the price tag of a medicine?
Episode #3 - A gene therapy story, breaking down Incyte’s future, and was Gottlieb wrong to try?
What’s it like to watch gene therapy happen? Is the next big cancer clinical trial going to work? And is “right to try” going to defang the FDA?
Episode #2 - Theranos’s fate, biotech’s awkward SXSW, and a word on cow loogies
Did Elizabeth Holmes get off easy? Why does biotech bother with SXSW? And what does shoving a tube into a dead cow’s throat have to do with biotech?
Episode #1 - Shkreli's sentence, biotech froth, and a blood party
How long is Martin Shkreli going to be in prison? Is the biotech bubble about to burst? And what's it like to attend a blood-swapping gala? Listen to our first episode of, "The Readout LOUD."
Coming soon: "The Readout LOUD"
An introduction to a new weekly biotech podcast from STAT.